A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Completed · Phase 2
Conditions studied: Advanced Multiple Myeloma
In brief
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study. Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.
Key facts
- Study ID
- NCT02092922
- Run by
- Pfizer
- People needed
- 154
- Starts
- 2014-05-01
- Expected to finish
- 2017-09-05
- Last updated by the study team
- 2020-10-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- University of California, San Francisco Medical Center — San Francisco, California, United States
- University of Colorado — Aurora, Colorado, United States
- Colorado Blood Cancer Institute — Denver, Colorado, United States
- Yale Comprehensive Cancer Center — New Haven, Connecticut, United States
- Emory University, Winship Cancer Institute — Atlanta, Georgia, United States
- Northwestern University — Chicago, Illinois, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Decatur Memorial Hospital — Decatur, Illinois, United States
- University of Kansas Cancer Center and Medical Pavilion — Westwood, Kansas, United States
- University of Kentucky — Lexington, Kentucky, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
- Tufts Medical Center — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Washington University in St. Louis — St Louis, Missouri, United States
- Nebraska Hematology Oncology, P.C. — Lincoln, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Mount Sinai Medical Center — New York, New York, United States
- NY Presbyterian - Weill Cornell Medical Center — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Duke Cancer Center — Durham, North Carolina, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- UAB Comprehensive Cancer Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.